DEVELOPMENT OF DIAGNOSTIC APPROACHES AND IMPROVEMENT OF PREVENTION OF NEPHROCARDIAL SYNDROME IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
DOI:
https://doi.org/10.55640/Keywords:
type 2 diabetes mellitus, nephrocardial syndrome, diabetic kidney disease, cardiovascular risk, albuminuria, eGFR, NT-proBNP, early diagnosis, prevention, cardiorenal protectionAbstract
This thesis is devoted to the development of diagnostic approaches and improvement of prevention of nephrocardial syndrome in patients with type 2 diabetes mellitus. Type 2 diabetes is associated with a high burden of renal and cardiovascular complications, and modern evidence shows that kidney and heart dysfunction in these patients should be considered as interconnected pathological processes rather than separate clinical problems. Early markers of kidney injury, particularly albuminuria and reduced estimated glomerular filtration rate, are closely associated with increased cardiovascular risk and may serve as key indicators for early diagnosis of nephrocardial syndrome. The study is based on analysis of contemporary guidelines and scientific publications devoted to diabetic kidney disease, chronic kidney disease risk management, cardiovascular–kidney–metabolic syndrome, and biomarker-based prediction of cardiorenal complications. Particular attention is given to routine diagnostic indicators such as UACR, eGFR, blood pressure, glycemic control, and lipid profile, as well as to additional tools including echocardiography and NT-proBNP. Recent data suggest that NT-proBNP may improve prediction of cardiovascular and renal complications in patients with type 2 diabetes and may therefore strengthen early diagnostic algorithms. The thesis concludes that effective diagnosis and prevention of nephrocardial syndrome require a complex and integrated approach. Early screening, risk stratification, and timely initiation of cardiorenal-protective treatment can reduce progression of kidney disease, lower cardiovascular risk, and improve long-term outcomes in patients with type 2 diabetes.Downloads
References
[1] World Health Organization. Diabetes. WHO Fact Sheet.
[2] American Diabetes Association. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes. Diabetes Care.
[3] KDIGO. 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
[4] American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory.
[5] Pabel S, et al. Cardiorenal syndrome and diabetes: an evil pairing. Frontiers in Cardiovascular Medicine.
[6] Rangaswami J, et al. Albuminuria and Heart Failure. ACC/AHA review materials.
[7] Diabetologia study. NT-proBNP improves prediction of cardiorenal complications in type 2 diabetes. Diabetologia, 2024.
[8] Bakris GL, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2020.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India